Sino Biopharm’s invoX Acquires F-Star, a UK Bispecific Company, for $161 Million
publication date: Jun 23, 2022
invoX Pharma, a Sino Biopharm subsidiary, will pay $161 million to acquire F-Star, a Cambridge, UK clinical stage company developing bispecific drugs for immunotherapies. F-star’s platform technology pioneers the use of tetravalent (2+2) bispecific antibodies. These antibodies target two different antigens and are paired with a unique set of pharmacology agents to activate an immune reaction in the tumor microenvironment. F-Star has four candidates in clinical trials, three from its tetravalent platform and one next-gen STING agonist. invoX, located in the UK, is responsible for Sino Biopharma’s R&D and business development outside of China. More details....
Stock Symbols: (HK: 1177) (NSDQ: FSTX)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.